Low testosterone (hypogonadism) affects an estimated 2–6% of men under 40 and up to 20–40% of men over 60, though many cases go undiagnosed for years.
The Endocrine Society defines hypogonadism as a morning total testosterone below 300 ng/dL, confirmed on at least two separate measurements.
Symptoms span six body systems — sexual function, body composition, mood, energy, cognition, and bone health — and no single symptom is diagnostic on its own.
Diagnosis requires both consistent symptoms and confirmed low serum testosterone; lab values alone are not sufficient.
Testosterone levels decline naturally at approximately 1–2% per year after age 30–35, but clinically significant hypogonadism is not a normal part of aging.
Obesity, type 2 diabetes, obstructive sleep apnea, and chronic opioid use are strongly associated with secondary hypogonadism and may cause or worsen it.
Published November 17, 2026 · Last updated November 17, 2026 · Reviewed by [Your Physician Name], MD
Low testosterone — clinically referred to as male hypogonadism — is one of the most underdiagnosed conditions in men’s health. The signs of low testosterone are often gradual in onset, affect multiple organ systems simultaneously, and are frequently attributed to stress, aging, or lifestyle factors rather than investigated as a potential hormonal deficiency.
The two most commonly reported symptoms are persistent fatigue and reduced sex drive. However, clinical research consistently shows that low testosterone also affects mood, body composition, bone density, cognitive function, and metabolic health in ways that significantly impact quality of life. Because no single symptom points definitively to testosterone deficiency, evaluation requires a structured clinical approach combining symptom assessment with confirmed laboratory findings.
This article outlines the evidence-based signs and symptoms of low testosterone organized by body system, the diagnostic criteria used by major medical organizations, the conditions most commonly associated with hypogonadism, and guidance on when to seek a physician evaluation. It is intended as an educational resource and does not constitute medical advice.
What Is Low Testosterone? Clinical Definition and Prevalence
Testosterone is the primary male sex hormone, produced mainly by Leydig cells in the testes under stimulation from luteinizing hormone (LH), which is released by the pituitary gland in response to gonadotropin-releasing hormone (GnRH) from the hypothalamus. This signaling chain — the hypothalamic-pituitary-testicular (HPT) axis — regulates testosterone production throughout a man’s life.
Testosterone plays a central role in male reproductive development, maintenance of muscle mass and bone density, red blood cell production, fat distribution, mood regulation, and cognitive function. When this hormone falls below the threshold required for normal physiological function, the resulting condition is called hypogonadism.
How Is Low Testosterone Defined Clinically?
The Endocrine Society’s 2018 Clinical Practice Guideline — the most widely referenced standard in the United States — defines male hypogonadism as a morning total testosterone level below 300 ng/dL (10.4 nmol/L), confirmed on at least two separate measurements taken in the morning (typically between 7:00 and 10:00 AM), in the presence of consistent signs and symptoms.
It is important to understand that testosterone values alone do not establish a diagnosis. The guideline explicitly states that testosterone therapy should be recommended only to men with both confirmed biochemical evidence of testosterone deficiency and symptomatic presentation. Many men with levels in the low-normal range (300–400 ng/dL) remain asymptomatic; others with similar values experience significant symptoms — a variation that reflects differences in androgen receptor sensitivity, sex hormone-binding globulin (SHBG) levels, and overall health status.
How Common Is It?
Estimates of prevalence vary depending on the diagnostic criteria used and the population studied. A 2014 systematic review published in The Journal of Hormones found that the prevalence of biochemically confirmed hypogonadism ranges from approximately 2–6% in men under 40 to 20–40% in men over 60. Among men with obesity, type 2 diabetes, or metabolic syndrome, prevalence may exceed 50%.
Despite these figures, the condition is frequently underdiagnosed. Many men normalize their symptoms — attributing fatigue, mood changes, and reduced libido to work stress, aging, or relationship dynamics — and do not present for evaluation until symptoms become severe.
Primary vs Secondary Hypogonadism
The underlying cause of testosterone deficiency matters clinically, as it affects both the diagnostic workup and the long-term management approach:
Primary hypogonadism originates in the testes themselves (e.g., Klinefelter syndrome, testicular injury, prior chemotherapy or radiation). LH and FSH are typically elevated as the pituitary attempts to compensate for insufficient testicular output.
Secondary hypogonadism originates in the hypothalamus or pituitary (e.g., pituitary adenoma, obesity-related suppression, opioid use, hyperprolactinemia). LH and FSH are low or inappropriately normal despite low testosterone.
Mixed hypogonadism involves dysfunction at multiple levels of the HPT axis, commonly seen in older men and those with significant metabolic disease.
Sexual and Reproductive Signs of Low Testosterone
Sexual symptoms are the most commonly reported manifestation of testosterone deficiency and are frequently the reason men first seek evaluation. They are also among the most specific — meaning they correlate more reliably with low testosterone than many other symptoms.
Reduced Libido
Decreased sexual desire is the hallmark symptom of male hypogonadism. A systematic review published in The Journal of Clinical Endocrinology & Metabolism in 2020 found that libido correlated more reliably with total testosterone levels than any other single symptom. The decline in sexual interest is often gradual — many men report that they simply “stopped noticing” their reduced drive rather than experiencing a sudden change — which contributes to delayed presentation and diagnosis.
Erectile Dysfunction
Testosterone plays a modulatory role in erectile physiology, particularly through its support of nitric oxide synthase activity in penile tissue. Research suggests that testosterone deficiency may contribute to erectile dysfunction (ED) in some men, particularly when other causes — vascular, neurological, or psychogenic — have been evaluated or excluded. A 2016 meta-analysis in The Journal of Sexual Medicine found that hypogonadal men had significantly higher rates of ED than eugonadal controls. However, ED in the context of low testosterone almost always involves multiple contributing factors, and testosterone deficiency as a sole cause of ED is less common than combined etiologies.
Reduced Ejaculatory Volume and Fertility Impact
Testosterone is essential for spermatogenesis. Men with significant testosterone deficiency may notice decreased ejaculate volume and, on laboratory evaluation, impaired sperm parameters including count, motility, and morphology. This is particularly relevant for men of reproductive age considering family planning. For a detailed discussion of this relationship, see our guide on TRT and fertility.
Physical and Body Composition Changes
Loss of Muscle Mass and Strength
Testosterone has well-established anabolic effects on skeletal muscle. It promotes muscle protein synthesis, increases the number of muscle satellite cells, and reduces markers of muscle catabolism. In men with hypogonadism, there is often a measurable decline in lean body mass, grip strength, and overall physical function. The Testosterone Trials — a landmark series of studies published in JAMA in 2016 — found that older men with low testosterone had significantly reduced lean mass and self-reported physical function compared to age-matched controls with normal testosterone levels.
Clinically, this may present as reduced exercise tolerance, difficulty with tasks that were previously routine (climbing stairs, carrying groceries), and a subjective sense of physical weakness that develops gradually over months to years.
Increased Body Fat, Particularly Abdominal
Testosterone influences fat distribution throughout the body. Low testosterone is associated with increased adiposity — particularly visceral fat accumulation in the abdominal region. Adipose tissue contains the enzyme aromatase, which converts testosterone to estradiol; excess body fat therefore creates a feedback cycle in which fat accumulation may further suppress testosterone. A 2019 review in Obesity Reviews described a strong bidirectional relationship between obesity and testosterone deficiency, noting that each condition worsens the other and that addressing one frequently improves the other.
Gynecomastia
Enlarged or tender breast tissue may develop in some men with testosterone deficiency when the ratio of testosterone to estradiol falls. This can occur even when absolute estradiol levels are within the reference range, if testosterone is sufficiently reduced. Gynecomastia has multiple potential causes and requires a full hormonal evaluation — including total testosterone, estradiol, LH, FSH, and prolactin — to identify the underlying etiology.
Reduced Body and Facial Hair
Testosterone supports the development and maintenance of androgenic hair patterns. Men with significant or long-standing testosterone deficiency may notice gradual thinning of body hair in androgen-dependent areas — axillary, pubic, and facial hair — as well as changes in skin texture. These changes are more pronounced in primary hypogonadism than in secondary or age-related forms.
Mood, Psychological, and Cognitive Signs
Depressed Mood and Irritability
Several cross-sectional and longitudinal studies have documented a clinically meaningful association between low testosterone and depressive symptoms in men. A 2019 meta-analysis published in JAMA Psychiatry (Walther et al.) analyzed 27 randomized controlled trials and found a statistically significant association between testosterone deficiency and elevated depressive symptom scores. Men with hypogonadism frequently report low mood, reduced sense of well-being, irritability, emotional blunting, and diminished quality of life independent of other symptoms.
The relationship is bidirectional: depression itself can suppress GnRH secretion and reduce testosterone through the hypothalamic-pituitary axis. This creates a cycle in which both conditions reinforce each other and are both clinically underdiagnosed and undertreated. A psychiatric and endocrine evaluation is warranted when these symptoms co-occur.
Persistent Fatigue and Low Energy
Fatigue is the most commonly reported non-sexual symptom of testosterone deficiency in clinical practice. It is also the least specific, as fatigue may result from thyroid dysfunction, anemia, sleep disorders, cardiovascular disease, depression, nutritional deficiencies, and many other conditions. In the context of other symptoms and confirmed low testosterone, fatigue is a recognized manifestation of hypogonadism. The Testosterone Trials found measurable improvements in self-reported energy and vitality in some older men with hypogonadism.
Cognitive Changes
Testosterone receptors are present throughout the brain, including the hippocampus, prefrontal cortex, and amygdala. Emerging research suggests that testosterone may play a role in certain aspects of cognitive function in men — particularly spatial memory, verbal memory, and processing speed. Some men with hypogonadism report subjective difficulty concentrating, forgetfulness, or the colloquially described “brain fog.” A 2019 study published in Frontiers in Endocrinology found associations between lower testosterone levels and reduced scores on cognitive performance tests in older men, though the clinical significance and causality of these findings remain under active investigation.
Bone Density and Metabolic Health
Reduced Bone Mineral Density
Testosterone plays a critical role in maintaining bone mineral density (BMD) in men, both through direct androgen receptor-mediated effects and indirectly through its aromatization to estradiol, which also contributes significantly to male bone health. Long-standing hypogonadism is a recognized risk factor for osteopenia and osteoporosis in men, and fragility fractures in hypogonadal men are well-documented. The American College of Physicians recommends BMD evaluation in men with known hypogonadism, particularly those with other risk factors for bone loss such as long-term glucocorticoid use, low body weight, or family history of osteoporosis.
Metabolic and Cardiovascular Risk Markers
Low testosterone is independently associated with several markers of metabolic dysregulation, including insulin resistance, elevated fasting glucose, dyslipidemia (specifically lower HDL and higher triglycerides), and increased visceral adiposity. These associations are supported by a substantial body of epidemiological literature and have led to recognition of testosterone deficiency as a component of metabolic syndrome in some clinical frameworks.
A large-scale observational study published in Circulation (2016) found that men with lower total testosterone had significantly higher rates of metabolic syndrome, type 2 diabetes, and cardiovascular disease markers at baseline. The causal direction of these associations remains a subject of active research.
Summary: Signs of Low Testosterone by Body System
[table id=3 /]
Medical Conditions Commonly Associated With Low Testosterone
Testosterone deficiency rarely occurs in isolation. Several common medical conditions are strongly associated with hypogonadism, either as contributing causes, as consequences, or as bidirectional relationships:
Obesity and Metabolic Syndrome
Excess visceral adiposity suppresses testosterone through multiple mechanisms: increased aromatase activity in adipose tissue increases conversion of testosterone to estradiol, while insulin resistance and elevated leptin levels suppress GnRH and LH secretion at the hypothalamic and pituitary levels. The relationship is bidirectional — low testosterone promotes fat accumulation, and fat accumulation further suppresses testosterone.
Type 2 Diabetes
Men with type 2 diabetes have testosterone levels approximately 25–30% lower than those without the condition, on average. The mechanisms include insulin resistance, hypothalamic-pituitary dysfunction, and in some cases peripheral neuropathy affecting testicular blood flow. Screening for testosterone deficiency is recommended in men with poorly controlled type 2 diabetes who present with symptoms consistent with hypogonadism.
Obstructive Sleep Apnea
Testosterone is predominantly produced during sleep, with the largest surge occurring during REM sleep. Untreated obstructive sleep apnea (OSA) — which fragments sleep architecture and reduces REM sleep time — has been associated with suppressed testosterone levels independent of obesity. Men with symptomatic hypogonadism who also report loud snoring, witnessed apneas, daytime somnolence, or non-restorative sleep should be evaluated for OSA prior to any hormonal intervention, as treating OSA alone may partially improve testosterone levels.
Chronic Opioid Use
Exogenous opioids suppress GnRH secretion in the hypothalamus and reduce LH pulsatility, resulting in secondary hypogonadism — a condition known as opioid-induced androgen deficiency (OPIAD). This is a recognized and frequently underdiagnosed complication of long-term opioid therapy for both cancer and non-cancer pain. Men on chronic opioid regimens should be monitored for signs and symptoms of testosterone deficiency.
Pituitary Disorders and Elevated Prolactin
Benign pituitary tumors — particularly prolactinomas — suppress LH and FSH secretion and are an important cause of secondary hypogonadism, especially in younger men. Elevated serum prolactin on laboratory evaluation is an indication for pituitary MRI. Additional pituitary pathologies including growth hormone deficiency, Cushing’s disease, and hemochromatosis may also suppress the HPT axis.
Conditions Associated With Secondary Hypogonadism
[table id=4 /]
How Testosterone Deficiency Is Diagnosed: The Clinical Process
A diagnosis of hypogonadism requires a structured evaluation — not simply a single laboratory value. The standard approach recommended by the Endocrine Society includes the following steps:
Step 1: Symptom Assessment
The physician reviews the patient’s symptom profile using validated questionnaires such as the Aging Males’ Symptoms (AMS) scale or the Androgen Deficiency in the Aging Male (ADAM) questionnaire, alongside a detailed medical history, current medications, and lifestyle factors. It is important to identify potentially reversible causes of low testosterone (such as obesity, sleep apnea, or opioid use) before initiating any hormonal evaluation.
Step 2: Morning Serum Testosterone
Blood is drawn in the morning (7:00–10:00 AM) when testosterone levels are at their daily peak. Total testosterone is the initial measurement. If the result is borderline or if SHBG abnormalities are suspected (as in obesity, hyperthyroidism, or liver disease), free testosterone is calculated or directly measured.
Step 3: Confirmatory Testing on a Second Day
A single low testosterone measurement is not sufficient for diagnosis. The Endocrine Society recommends confirmation with a repeat measurement on a different day, with concurrent measurement of LH and FSH to determine whether hypogonadism is primary (testicular origin, elevated LH/FSH) or secondary (hypothalamic-pituitary origin, low or normal LH/FSH).
Step 4: Evaluation of Underlying Causes
Depending on the clinical picture, additional testing may include prolactin, estradiol, SHBG, CBC, comprehensive metabolic panel, thyroid function, iron studies, and in selected cases, pituitary MRI. For more detail on the laboratory workup before initiating any hormonal evaluation, see our guide to pre-treatment lab testing.
Step 5: Rule Out Reversible Causes First
Before pursuing hormonal treatment, clinicians typically attempt to address reversible contributors to low testosterone. Significant weight loss in obese patients, treatment of obstructive sleep apnea, discontinuation of contributing medications, and optimization of sleep quality have all been shown in studies to raise endogenous testosterone in some men. This approach is consistent with best-practice guidelines and may resolve the deficiency without additional intervention.
Experiencing these symptoms?
Persistent fatigue, low libido, mood changes, or unexplained loss of muscle mass that affects your quality of life warrants a physician evaluation — not self-diagnosis. Our clinical team reviews your complete symptom history and orders the appropriate laboratory panel to determine whether a hormonal evaluation is indicated.
Not every man who feels tired or notices a reduced sex drive has low testosterone. The decision to pursue an evaluation should be based on the presence of multiple symptoms that have persisted for more than a few weeks, that are not clearly explained by another cause, and that are affecting quality of life in meaningful ways.
The following combinations of symptoms are more likely to reflect genuine testosterone deficiency and warrant a physician evaluation:
Reduced libido combined with persistent fatigue and mood changes
Unexplained loss of muscle mass or significant changes in body composition without lifestyle changes
Erectile dysfunction in a younger man with no obvious cardiovascular or psychological cause
Depressive symptoms that are not responding to standard treatment, particularly in men with other metabolic risk factors
Concerns about fertility combined with other hormonal symptoms
A single symptom in isolation — especially fatigue — rarely warrants testosterone testing as the first step. Your physician will determine which laboratory tests are appropriate and will interpret results in the context of your complete clinical picture. For men wondering whether their symptoms warrant formal evaluation, our guide to how to know if you need TRT provides additional clinical context.
Frequently Asked Questions
What are the most common signs of low testosterone in men?
The most commonly reported symptoms of low testosterone are reduced libido (sex drive) and persistent fatigue, followed by depressed mood, loss of muscle mass, increased body fat, and difficulty concentrating. However, no single symptom is diagnostic on its own. Because these symptoms are shared by many conditions, a physician evaluation with laboratory testing is required to determine whether they are related to testosterone deficiency specifically.
At what testosterone level do symptoms typically appear?
Symptoms most commonly emerge at total testosterone levels below 300 ng/dL, which is the threshold the Endocrine Society uses for clinical diagnosis. However, there is considerable individual variation — some men develop significant symptoms at 350 ng/dL, while others remain asymptomatic at 250 ng/dL. This variation is influenced by androgen receptor sensitivity, SHBG levels (which affect the amount of biologically active free testosterone), and overall health status.
Can low testosterone cause depression?
Research suggests a clinically meaningful association between hypogonadism and depressive symptoms in some men. A 2019 meta-analysis in JAMA Psychiatry found that men with testosterone deficiency had significantly higher rates of depressive symptoms compared to eugonadal men. The relationship is bidirectional — depression can also suppress testosterone through its effects on the hypothalamic-pituitary axis. When both conditions co-occur, evaluation by both a mental health professional and an endocrinologist or urologist may be warranted.
Can low testosterone cause weight gain?
Low testosterone is associated with increased body fat — particularly visceral (abdominal) fat — in some men. The relationship is bidirectional: low testosterone promotes fat accumulation, and increased adipose tissue suppresses testosterone further through aromatase activity. Men with significant central obesity and symptoms of testosterone deficiency should have both conditions evaluated together. For more detail, see our article on low testosterone and weight gain.
How is low testosterone different from normal aging?
Testosterone levels naturally decline at approximately 1–2% per year beginning around age 30–35. This gradual decline is a normal part of male physiology, and many men maintain testosterone levels within the normal range well into their 70s and 80s. Clinically significant hypogonadism — meaning levels below 300 ng/dL with consistent symptoms — is not simply a consequence of normal aging and should not be dismissed as such. The distinction matters because testosterone deficiency, regardless of age, may warrant evaluation and management if it is significantly affecting quality of life.
Is fatigue always a sign of low testosterone?
No. Fatigue is one of the most nonspecific symptoms in medicine and may result from thyroid dysfunction, anemia, sleep disorders (especially sleep apnea), depression, cardiovascular disease, nutritional deficiencies, overtraining, medication side effects, and many other causes. A physician evaluation for persistent fatigue should include a broad laboratory panel — not just testosterone — to identify the underlying cause or combination of causes. Low testosterone may be one contributing factor, but it is rarely the only one.
Can lifestyle changes improve low testosterone?
In men whose testosterone deficiency is related to modifiable risk factors — particularly obesity, poor sleep, obstructive sleep apnea, sedentary lifestyle, or excessive alcohol use — addressing those factors may raise endogenous testosterone levels in some cases. Research shows that significant weight loss in obese men can raise total testosterone by 50–100 ng/dL or more. However, lifestyle interventions alone are unlikely to fully correct testosterone levels in men with clinically significant hypogonadism. Physician evaluation is needed to determine the appropriate approach for each individual.
When should I see a doctor about symptoms of low testosterone?
Seek a physician evaluation if you are experiencing a combination of symptoms consistent with testosterone deficiency — particularly reduced libido, persistent fatigue, significant mood changes, unexplained loss of muscle mass, or sexual dysfunction — that have persisted for more than a few weeks, are not explained by another obvious cause, and are affecting your quality of life. Your physician will determine which laboratory tests are appropriate based on your complete clinical history. Do not attempt to self-diagnose or self-treat based on symptoms alone.
Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. The signs and symptoms described here may be associated with many conditions other than testosterone deficiency. Only a qualified physician can evaluate your individual health history, symptoms, and laboratory results to establish an accurate diagnosis. Do not attempt to self-diagnose or self-treat based on the information in this article. If you have concerns about your hormonal health, schedule a consultation with a qualified clinician.
References
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229
Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611–624. doi:10.1056/NEJMoa1506119
Walther A, Breidenstein J, Miller R. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2019;76(1):31–40. doi:10.1001/jamapsychiatry.2018.2734
Zarotsky V, Huang MY, Carman W, et al. Systematic literature review of the epidemiology of nongenetic forms of hypogonadism in adult males. J Hormones. 2014;2014:190347. doi:10.1155/2014/190347
Grossmann M, Matsumoto AM. A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management. J Clin Endocrinol Metab. 2017;102(3):1067–1075. doi:10.1210/jc.2016-3580
Rastrelli G, Carter EL, Ahern T, et al. Development of and Recovery from Secondary Hypogonadism in Aging Men: Prospective Results from the EMAS. J Clin Endocrinol Metab. 2015;100(8):3172–3182. doi:10.1210/jc.2015-1571
Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT randomized trials. Best Pract Res Clin Endocrinol Metab. 2013;27(4):557–579. doi:10.1016/j.beem.2013.05.002
Atlantis E, Fahey P, Cochrane B, Smith S. Bidirectional associations between clinically relevant depression or anxiety and COPD: a systematic review and meta-analysis. Chest. 2013;144(3):766–777.